|
1
|
Weingart SN, Brown E, Bach PB, Eng K,
Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer
LN, et al: NCCN Task Force Report: Oral chemotherapy. J Natl Compr
Canc Netw. 6 (Suppl 3):S1–S14. 2008.PubMed/NCBI
|
|
2
|
Timmers L, Beckeringh JJ, van Herk-Sukel
MP, Boven E and Hugtenburg JG: Use and costs of oral anticancer
agents in the Netherlands in the period 2000-2008.
Pharmacoepidemiol Drug Saf. 21:1036–1044. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Mancini R, Kaster M, Vu B, Modlin J and
Wilson B: Implementation of a pharmacist managed interdisciplinary
oral chemotherapy program in a community cancer center. J Hematol
Oncol Pharm. 1:23–30. 2011.
|
|
4
|
Twelves C, Gollins S, Grieve R and Samuel
L: A randomised cross-over trial comparing patient preference for
oral capecitabine and 5-fluorouracil/leucovorin regimens in
patients with advanced colorectal cancer. Ann Oncol. 17:239–245.
2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Brooks GA, Kansagra AJ, Rao SR, Weitzman
JI, Linden EA and Jacobson JO: A clinical prediction model to
assess risk for chemotherapy-related hospitalization in patients
initiating palliative chemotherapy. JAMA Oncol. 1:441–447.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hassett MJ, O'Malley AJ, Pakes JR,
Newhouse JP and Earle CC: Frequency and cost of
chemotherapy-related serious adverse effects in a population sample
of women with breast cancer. J Natl Cancer Inst. 98:1108–1117.
2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Koich G: Outpatient management of
anticancer drug trials and the current state of outpatient
chemotherapy in Japan. Pharma Medica. 28:61–65. 2010.(In
Japanese).
|
|
8
|
Prince RM, Atenafu EG and Krzyzanowska MK:
Hospitalizations during systemic therapy for metastatic lung
cancer: A systematic review of real world vs clinical trial
outcomes. JAMA Oncol. 1:1333–1339. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Stein J and Mann J: Specialty pharmacy
services for patients receiving oral medications for solid tumors.
Am J Health Syst Pharm. 73:775–796. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Patel JM, Holle LM, Clement JM, Bunz T,
Niemann C and Chamberlin KW and Chamberlin KW: Impact of a
pharmacist-led oral chemotherapy-monitoring program in patients
with metastatic castrate-resistant prostate cancer. J Oncol Pharm
Pract. 22:777–783. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lam MS and Cheung N: Impact of oncology
pharmacist-managed oral anticancer therapy in patients with chronic
myelogenous leukemia. J Oncol Pharm Pract. 22:741–748.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Schneider SM, Adams DB and Gosselin T: A
tailored nurse coaching intervention for oral chemotherapy
adherence. J Adv Pract Oncol. 5:163–172. 2014.PubMed/NCBI
|
|
13
|
Kimura M, Go M, Iwai M, Usami E and
Yoshimura T: Evaluation of the role and usefulness of a pharmacist
outpatient service for patients undergoing monotherapy with oral
anti-cancer agents. J Oncol Pharm Pract. 23:413–421.
2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Arakawa-Todo M, Yoshizawa T, Zennami K,
Nishikawa G, Kato Y, Kobayashi I, Kajikawa K, Yamada Y, Matsuura K,
Tsukiyama I, et al: Management of adverse events in patients with
metastatic renal cell carcinoma treated with sunitinib and clinical
outcomes. Anticancer Res. 33:5043–5050. 2013.PubMed/NCBI
|
|
15
|
NCI Guidelines for Investigators: Adverse
event reporting requirements for DCTD (CTEP and CIP) and DCP INDs
and IDEs. Page 5. urihttps://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdfsimplehttps://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf.
Accessed February 29, 2012.
|
|
16
|
Uramoto H, Iwashige A, Kagami S and
Tsukada J: Prediction of emergency hospitalization of outpatients
receiving cancer chemotherapy. Anticancer Res. 27:1133–1136.
2007.PubMed/NCBI
|
|
17
|
McKenzie H, Hayes L, White K, Cox K,
Fethney J, Boughton M and Dunn J: Chemotherapy outpatients'
unplanned presentations to hospital: A retrospective study. Support
Care Cancer. 19:963–969. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rashid N, Koh HA, Baca HC, Li Z, Malecha
S, Abidoye O and Masaquel A: Clinical impact of
chemotherapy-related adverse events in patients with metastatic
breast cancer in an integrated health care system. J Manag Care
Spec Pharm. 21:863–871. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Aprile G, Pisa FE, Follador A, Foltran L,
De Pauli F, Mazzer M, Lutrino S, Sacco CS, Mansutti M and Fasola G:
Unplanned presentations of cancer outpatients: A retrospective
cohort study. Support Care Cancer. 21:397–404. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Pittman NM, Hopman WM and Mates M:
Emergency room visits and hospital admission rates after curative
chemotherapy for breast cancer. J Oncol Pract. 11:120–125.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hassett MJ, Rao SR, Brozovic S, Stahl JE,
Schwartz JH, Maloney B and Jacobson JO: Chemotherapy-related
hospitalization among community cancer center patients. Oncologist.
16:378–387. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820.
2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Okusaka T, Funakoshi A, Furuse J, Boku N,
Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for
metastatic pancreatic cancer. Cancer Chemother Pharmacol.
61:615–621. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Naeim A, Dy SM, Lorenz KA, Sanati H,
Walling A and Asch SM: Evidence-based recommendations for cancer
nausea and vomiting. J Clin Oncol. 26:3903–3910. 2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Geyer CE, Forster J, Lindquist D, Chan S,
Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A,
Kaufman B, et al: Lapatinib plus capecitabine for HER2-positive
advanced breast cancer. N Engl J Med. 355:2733–2743.
2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kaori N, Fumiko S, Eiko K and Naoko S:
Relationship between Symptom Experience and QOL for Cancer
Outpatients Receiving Molecular Targeted Therapy. J Jpn Soc Cancer
Nursing. 28:5–12. 2014.
|
|
29
|
Taplitz RA, Kennedy EB and Flowers CR:
Outpatient management of fever and neutropenia in adults treated
for malignancy: American society of clinical oncology and
infectious diseases society of america clinical practice guideline
update summary. J Oncol Pract. 14:250–255. 2018.PubMed/NCBI View Article : Google Scholar
|
